CORRECTING and REPLACING Polio Vaccination Campaign Planned in Afghanistan with PharmaJet® Tropis® ID Delivery System

• PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan.
• PharmaJet’s award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia.
• The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability.

GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated August 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement.

The updated release reads:

Polio Vaccination Campaign Planned in Afghanistan with PharmaJet^® Tropis^® ID Delivery System

• PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan.
• PharmaJet’s award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia.
• The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability.

PharmaJet^®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan.

Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan’s polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission.

“We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,” said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. “We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability¹ previously seen with Tropis ID delivered fIPV in Pakistan,¹ Somalia,² and Nigeria³.”

Refer to Instructions for Use to ensure safe injections and to review risks.

*NOTE: We regret that the content of this news release on August 19, 2025 was originally published without UNICEF/WHO consent. Operational details remain subject to national authorities and partners agreement.

¹ Daly, C et al, Needle-free injectors for mass administration of fractional dose inactivated poliovirus vaccine (fIPV) in Karachi, Pakistan: A survey of caregiver and vaccinator acceptability, Vaccine, Volume 38 Issue 8, 18 February, 2020, Pages 1893-1898
² Nouh, K et al, Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia, Springer Nature Volume 2 article number 16 (2024)
³ Biya, O et al, Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine — Sokoto State, Nigeria, November 2022, CDC Morbidity and Mortality Weekly report, November 24, 2023 / 72(47);1290–1291

About PharmaJet

The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis^® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.